Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Oncotelic Therapeutics, Inc. OTLC OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
22/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Oncotelic Therapeutics, Inc. (OTLC) is a Biotechnology company in the Healthcare sector, currently trading at $0.04. It has a SharesGrow Score of 20/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $4.5B (loss), growing at -19010.2%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $13M against $8M equity (Debt-to-Equity (D/E) ratio 1.59, leveraged). Current ratio is 0.01 (tight liquidity). Debt-to-assets is 49.1%. Total assets: $27M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 25/100 (Fail), Health 0/100 (Fail), Moat 46/100 (Partial), Future ?/100 (Fail), Income ?/100 (Fail).

OTLC SharesGrow Score Overview

29/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OTLC

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
OTLC: -100%/yr revenue is, -19010.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
OTLC: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
—
HEALTH N/A
N/A
No analyst coverage available for this stock.
~
MOAT Partial
46/100
OTLC: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.02-0.11
Volume5.01K
Avg Volume (30D)298.04K
Market Cap$16.02M
Beta (1Y)-0.59
Share Statistics
EPS (TTM)-0.01
Shares Outstanding$404.4M
IPO Date1993-08-26
Employees26
CEOVuong Trieu
Financial Highlights & Ratios
EBITDA$-3.58B
Net Income$-4.52B
Operating Income$-3.58B
Total Cash$86.13K
Total Debt$13.09M
Net Debt$13M
Total Assets$26.68M
Price / Earnings (P/E)-3.6
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS6283411097

Price Chart

Track all markets on TradingView
OTLC
Oncotelic Therapeutics, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.02 52WK RANGE 0.11

People Also View

CMVLF
CMVLF
Cellectis S.A.
$3.08
-30.00%
 ALVR
ALVR
AlloVir, Inc.
$9.81
+4.14%
 BITRF
BITRF
Biotron Limited
$0.03
+0.00%
 CRPOF
CRPOF
Ceapro Inc.
$0.17
-13.04%
 PCSA
PCSA
Processa Pharmaceuticals, Inc.
$2.87
-0.35%
 SILO
SILO
Silo Pharma, Inc.
$0.40
-7.17%
 PKTX
PKTX
ProtoKinetix, Incorporated
$0.01
+47.66%
 VGLS
VGLS
VG Life Sciences Inc.
$0.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message